Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.7% above analysts’ estimates. Its GAAP profit of $0.53 per share was 17.3% below analysts’ consensus estimates.
Is now the time to buy PAHC? Find out in our full research report (it’s free for active Edge members).
Phibro Animal Health (PAHC) Q2 CY2026 Highlights:
- Revenue: $396.7 million vs analyst estimates of $371.6 million (4.8% year-on-year growth, 6.8% beat)
- EPS (GAAP): $0.53 vs analyst expectations of $0.64 (17.3% miss)
- Adjusted EBITDA: $55.9 million vs analyst estimates of $58.21 million (14.1% margin, 4% miss)
- EBITDA guidance for the upcoming financial year 2027 is $263 million at the midpoint, below analyst estimates of $264.7 million
- Operating Margin: 12.2%, up from 8.9% in the same quarter last year
- Market Capitalization: $1.47 billion
StockStory’s Take
Phibro Animal Health’s Q2 results reflected ongoing momentum across a diversified portfolio, with management attributing growth to strength in both its legacy Animal Health and Mineral Nutrition businesses. CEO Dani Bendheim cited “continuous sales momentum” and the integration of the Zoetis MFA portfolio as factors supporting the quarter’s performance. The company also benefited from operational efficiencies stemming from its Phibro Forward transformation program, which helped offset cost pressures and contributed to improved operating margin. Management acknowledged a challenging comparison for the acquired MFA portfolio but maintained that these results were in line with internal expectations.
Looking ahead, Phibro Animal Health’s forward guidance is shaped by both regulatory uncertainty and continued investment in core growth areas. Management expects minimal sales from virginiamycin in Brazil due to ongoing regulatory review, which CFO Glenn David described as the “key uncertainty” in planning for the coming year. The company is focusing on expanding its vaccine manufacturing capacity and leveraging efficiencies from recent facility closures, while also closely monitoring commodity price trends and market demand in its Mineral Nutrition segment. CEO Dani Bendheim emphasized priorities of advancing innovation and disciplined capital allocation to support long-term value creation.
Key Insights from Management’s Remarks
Management pointed to a combination of higher demand, successful integration of acquired products, and cost discipline as the primary drivers of the quarter’s performance, while also flagging regulatory and input cost headwinds.
- Legacy Animal Health strength: The core Animal Health business, including medicated feed additives (MFAs), nutritional specialties, and vaccines, showed steady growth, with legacy MFA sales up 11% in the quarter. Management attributed this to robust demand in North America and international markets, particularly in poultry and beef segments.
- Zoetis MFA integration: While sales from the acquired Zoetis MFA portfolio declined 11% due to a challenging comparison period, management stressed that overall integration has brought strategic benefits, including expanded product offerings and improved customer engagement, and expects this portfolio to remain a growth driver relative to the broader company.
- Mineral Nutrition momentum: The Mineral Nutrition segment delivered 20% sales growth, driven by higher demand for premixes and rising commodity prices for zinc and copper. However, management noted that while revenue growth was strong, EBITDA growth lagged due to only partial pass-through of increased material costs to customers.
- Phibro Forward transformation: The conclusion of the three-year Phibro Forward program has improved operational execution and cost discipline, contributing approximately $50 million in cumulative EBITDA gains versus the 2024 baseline. These capabilities are now embedded in day-to-day operations and expected to deliver ongoing efficiencies.
- Manufacturing footprint changes: The closure of the Chicago Heights facility was announced as a network optimization move following the MFA acquisition. Management expects this to deliver modest EBITDA benefits in the upcoming year and larger savings in subsequent years, while supporting a more efficient manufacturing network.
Drivers of Future Performance
Phibro’s outlook is shaped by regulatory uncertainties, margin management, and continued investment in vaccine capacity and portfolio expansion.
- Regulatory headwinds in Brazil: The company is assuming minimal contribution from virginiamycin sales in Brazil due to ongoing regulatory review, with any positive resolution representing potential upside. Management described the regulatory situation as a “very big political football” and is not factoring in a recovery until clarity improves post-election cycle.
- Margin and cost discipline: Flat gross margins are expected as efficiency gains from Phibro Forward and manufacturing optimization offset the negative margin impact from reduced virginiamycin sales. SG&A expenses are projected to grow slightly above revenue due to ongoing investment in capacity and R&D, but not materially so, according to CFO Glenn David.
- Vaccine and specialty growth focus: Elevated capital expenditures will support expanded vaccine manufacturing capacity in Ireland and Israel, as well as targeted growth in companion animal and nutritional specialties. Management sees these areas—along with select M&A opportunities—as the most promising for margin expansion and future revenue growth.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be tracking (1) regulatory developments in Brazil regarding virginiamycin’s therapeutic use, (2) the pace and impact of vaccine manufacturing capacity expansions in Ireland and Israel, and (3) the realization of cost savings from the Chicago Heights facility closure. Additional attention will be paid to commodity price dynamics in the Mineral Nutrition segment and the effectiveness of ongoing R&D investment in portfolio growth.
Phibro Animal Health currently trades at $36.35, in line with $36.09 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.